An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 13, Pages 3579-3590
Publisher
American Society of Hematology
Online
2011-07-20
DOI
10.1182/blood-2011-03-340364
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
- (2010) D. Yecies et al. BLOOD
- Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
- (2010) Tadeusz Robak et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- Mitochondria and cell death: outer membrane permeabilization and beyond
- (2010) Stephen W. G. Tait et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia
- (2009) R. W. Stam et al. BLOOD
- MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts
- (2009) Joslyn K. Brunelle et al. JOURNAL OF CELL BIOLOGY
- Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
- (2009) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia
- (2009) K D Mason et al. LEUKEMIA
- The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs
- (2009) L. M. High et al. MOLECULAR PHARMACOLOGY
- BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3
- (2008) A. Nordigarden et al. BLOOD
- Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
- (2008) C. Pepper et al. BLOOD
- Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
- (2008) M. Vogler et al. BLOOD
- Up-regulation of Mcl-1 Is Critical for Survival of Human Melanoma Cells upon Endoplasmic Reticulum Stress
- (2008) C. C. Jiang et al. CANCER RESEARCH
- Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer
- (2008) C. L. Hann et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started